Form 4 for IDXX Idexx Laboratories
Accepted 2025-02-18 00:00:00 ET · period of report 2025-02-13 · accession 0000874716-25-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-18 | 2025-02-14 | IDXX | Erickson Michael G | EVP | M - OptEx | $0.00 | +557 | 20.9K | +3% | $0 |
| D | 2025-02-18 | 2025-02-14 | IDXX | Erickson Michael G | EVP | F - Tax | $444.53 | -177 | 21.2K | -0.8% | -$78.7K |
| DM | 2025-02-18 | 2025-02-14 | IDXX | Erickson Michael G | EVP | M - OptEx | $0.00 | -557 | 0 | -100% | $0 |
| DM | 2025-02-18 | 2025-02-13 | IDXX | Erickson Michael G | EVP | A - Grant | $0.00 | +8,005 | 217 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-14 | M | A | 301 | $0.00 | 21,393.36 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-14 | M | A | 94 | $0.00 | 21,092.36 | D | — | — | |
| 3 | Common | Common Stock | 2025-02-14 | M | A | 93 | $0.00 | 20,998.36 | D | — | — | |
| 4 | Common | Common Stock | 2025-02-14 | M | A | 69 | $0.00 | 20,905.36 | D | — | — | |
| 5 | Common | Common Stock | 2025-02-14 | F | D | 177 | $444.53 | 21,216.36 | D | — | — | |
| 6 | Derivative | Restricted Stock Unit | 2025-02-14 | M | D | 301 | $0.00 | 903 | D | — · — to — | 301 Common Stock | (F8) Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2025. |
| 7 | Derivative | Restricted Stock Unit | 2025-02-14 | M | D | 94 | $0.00 | 188 | D | — · — to — | 94 Common Stock | (F7) Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2024. |
| 8 | Derivative | Restricted Stock Unit | 2025-02-14 | M | D | 93 | $0.00 | 92 | D | — · — to — | 93 Common Stock | (F6) Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023. |
| 9 | Derivative | Restricted Stock Unit | 2025-02-14 | M | D | 69 | $0.00 | 0 | D | — · — to — | 69 Common Stock | (F5) Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2022. |
| 10 | Derivative | Restricted Stock Unit | 2025-02-13 | A | A | 734 | $0.00 | 734 | D | — · — to — | 734 Common Stock | (F4) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. |
| 11 | Derivative | Restricted Stock Unit | 2025-02-13 | A | A | 734 | $0.00 | 734 | D | — · — to — | 734 Common Stock | (F3) Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026. |
| 12 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2025-02-13 | A | A | 6,320 | $0.00 | 6,320 | D | $459.76 · — to 2035-02-12 | 6,320 Common Stock | (F1) Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. |
| 13 | Derivative | Incentive Stock Option (right-to-buy) | 2025-02-13 | A | A | 217 | $0.00 | 217 | D | $459.76 · — to 2035-02-12 | 217 Common Stock | (F2) Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. |